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Complete surgical resection is the best hope for cure in patients with operable non-small cell lung cancer (NSCLC), yet the 5-year overall 
survival rate is only 23% to 67%, depending on stage, 
which is based on the size of the primary tumor, the 
presence or absence of invasion and lymph node in-
volvement.1 Forty to 60 percent of Stage IB and II pa-
tients will eventually experience relapse with two-thirds 
occurring systemically.2 On the basis that micrometas-
tases are responsible for disease recurrence in the ma-
jority of patients, the role of adjuvant chemotherapy has 
been examined extensively over the last few decades. 
However, the benefit of adjuvant treatment in terms 
of overall survival has only recently been confirmed in 
clinical trials.3-8
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BACKGROUND AND OBJECTIVES: poor compliance has been a common feature in clinical trials of adjuvant 
chemotherapy for nsclc with only 48% to 69% of patients completing all planned cycles. We retrospectively 
evaluated compliance and toxicity of platinum-based chemotherapy in the 2 years following recent reports of 
successful adjuvant chemotherapy trials for nsclc. 
PATIENTS AND METHODS: patients who received adjuvant chemotherapy after complete resection of nsclc 
between may 2003 and may 2005 were analyzed retrospectively. patient demographics, ecoG status, stage, 
pathologic subtype and type of surgery were recorded. the number of chemotherapy cycles, delays, dose reduc-
tions and change of chemotherapy were reported. 
RESULTS: fifty patients were identified. the median age was 62 years (38% stage i, 18% stage ii, 30% stage 
iii and 14% had multiple primary tumors of variable stages). twenty percent were ecoG ps2; only 12% had 
undergone pnemonectomy. forty-one patients (82%) started cisplatin/vinorelbine (three switched to carboplatin 
because of nephrotoxicity, and one switched to carboplatin/paclitaxel because of fatigue and vomiting). three 
patients received other cisplatin-based combinations; six received carboplatin-based treatment (one each be-
cause of advanced age and cardiac dysfunction and 4 because of preexisting neuropathy). eighty percent com-
pleted all treatment; 40% required a dose reduction and 58% required delays in treatment. six events of febrile 
neutropenia were reported in 5 patients and 5 patients required admission for toxicity. there were no toxic 
deaths. multivariate analysis showed no effect of age, gender, extent of surgery or ecoG status on compliance, 
need for treatment modification or toxicity. 
CONCLUSIONS: compared to historical trials, adjuvant platinum-based chemotherapy for resected nsclc is 
now accepted by patients and physicians with a high degree of compliance. 
Inadequate delivery of postoperative chemotherapy 
was a common feature in the trials conducted in the 
1970s and 1980s, and this was thought to be respon-
sible, among other factors, for the failure to show a con-
vincing benefit from the addition of adjuvant chemo-
therapy to surgical resection. In a critical review of 11 
randomized trials of cisplatin-based adjuvant regimens, 
only 50% (range 36%-76%) of patients received the full 
course of treatment.9 The poor compliance was likely 
secondary to the difficulty in delivering chemotherapy 
with its associated toxicities in the postoperative pe-
riod, and the substandard supportive care used in many 
if not most of the trials. Somewhat surprisingly, recent 
randomized trials have shown only marginally better 
compliance despite considerable improvements in sup-
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portive care medications available over the past decade. 
Those trials reported that only 48% to 69% of patients 
completed the planned cycles of chemotherapy. The 
Cancer and Leukemia Group B (CALGB) 9633 trial5 is 
an exception, with a compliance rate of 85% in patients 
with available compliance data (124 of 173 patients in 
the chemotherapy arm). 
Analyses of factors influencing compliance have rare-
ly been reported.10,11 Alam et al11 examined the patient 
and physician characteristics in the National Cancer 
Institute of Canada Clinical Trials Group (NCIC 
CTG) JBR.10 trial,4 and investigated the role they 
might have played in completion of adjuvant therapy. 
Only 48% of patients received the planned 4 cycles of 
vinorelbine and cisplatin and 13% and 29% of patients 
discontinued therapy because of toxicity or outright 
refusal, respectively. Pneumonectomy as opposed 
to lesser resection, advanced age and female gender, 
were associated with poor compliance. In this study, 
we evaluated retrospectively compliance with adjuvant 
chemotherapy and report the associated toxicity in 
patients treated after the recent publication of trials 
reporting a significant survival benefit from adjuvant 
chemotherapy.3-8
PATIENTS AND METHODS
Patients and Treatment 
Following approval by the Research Ethics Board of 
the University Health Network, patients were identi-
fied using an institutional cancer registry. All patients 
who received adjuvant chemotherapy after complete re-
section of operable non-small cell cancer between May 
2003 and May 2005, at the Princess Margaret Hospital 
Table 1. Patient Characteristics. 
Characteristics Number (%) (n=50) 
Age (years) 
   range (years) 50-78 
   median (years) 62 
Gender 
   male 25 (50) 
   Female 25 (50) 
ECOG Performance status 
   0-1 40 (80) 
   2 10 (20) 
Stage 
   I A 1 (2) 
   II B 18 (36) 
   II A 1 (2) 
   II B 8 (16) 
   III A 6 (12) 
   III B 9 (18) 
   2 separate primaries 5 (10) 
   3 separate primaries 2 (4) 
Surgery 
   Lobectomy 38 (76) 
   Pnemonectomy 6 (12) 
   Segmentectomy 3 (6) 
   Wedge resection 2 (4) 
   Lobectomy and wedge (same case) 1 (2) 
Table 2. regimens and doses of chemotherapy. 
Chemotherapy Number (%) (n=50) 
Cisplatin 75 mg/m2, day 1 
41 (82)* 
Vinorelbine 25 mg/m2, day 118 
Carboplatin AUC 6, day 1 
3 (6) 
Paclitaxel 175 mg/m2, day 1 
Cisplatin 25 mg/m2, day 1-3 
2 (4) 
Etoposide 100 mg/m2, days 1-3 
Carboplatin AUC 5, day 1 
2 (4) 
Gemcitabine 1250 mg/m2, days 1,8 
Cisplatin 75 mg/m2, day 1 
1(2) 
Gemcitabine 1250 mg/m2, days 1,8 
Carboplatin AUC 5, day 1 
1 (2) 
Vinorelbine 25 mg/m2, days 1,8 
AUC: Area Under the Curve ; *Four patients were then switched; three to carboplatin/
vinorelbine and one to carboplatin/paclitaxel. 
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and Mount Sinai Hospital, Toronto, were included in 
this review. Prior to May 2003, adjuvant chemotherapy 
was not routinely offered to this population outside of 
a clinical trial. 
Most patients received a platinum-based regimen. 
Based on the JB-10 trial, a combination of cisplatin/
vinorelbine was the most commonly used regimen. 
Some patients received combinations of carboplatin/
paclitaxel, carboplatin/vinorelbine, carboplatin/gem-
citabine, cisplatin/ etoposide or cisplatin/ gemcitabi-
ne. All patients were assessed clinically before starting 
chemotherapy to define their performance status and 
tolerability for chemotherapy. Baseline blood tests in-
cluding complete blood count, and renal and liver func-
tion tests were performed routinely for every patient. 
Clinical assessment and routine blood tests were re-
peated before each cycle of treatment. Delay or reduc-
tion of chemotherapy dosage was decided according to 
the clinical assessment. 
Data collection and analysis 
Data on patient demographics, ECOG status, stage and 
pathology of the tumor, in addition to the type of surgery 
were all collected. The type of the cisplatin-based com-
bination, total number of chemotherapy cycles, delays 
and reductions of the dosage were recorded. The use of 
adjuvant radiation was also recorded. The toxicities were 
graded according to the common toxicity criteria grading 
system.12 All admissions to hospital during chemothera-
py treatment were documented along with the reason for 
admission. The association between the completion of 
treatment and toxicity with the clinical parameters (age, 
gender, type of surgery and ECOG performance status) 
was investigated using the Fisher exact test. 
RESULTS 
Patient characteristics 
A total of 50 patients were identified between May 
2003 and May 2005. The median age was 62 years and 
50% were male (Table 1). Invasive adenocarcinoma was 
found in 29 patients (58%); 19 (38%) had Stage I, 9 
(18%) had Stage II and 15 (30%) had Stages II and III, 
and 7 patients (14%) had multiple primary tumors. Ten 
patients (20%) had an ECOG status of 2 at the time of 
starting adjuvant chemotherapy. Only 6 patients (12%) 
had undergone pneumectomy. 
Treatment regimens 
Forty-one patients (82%) were started on cisplatin/
vinorelbine, although 3 were switched to carbopla-
tin because of nephrotoxicity (Table 2). One patient 
switched to carboplatin/paclitaxel because of fatigue 
and vomiting. Three patients (6%) received different 
cisplatin-based combinations (cisplatin/etoposide, 2 
and cisplatin/gemcitabine, 1). Three patients (6%) re-
ceived carboplatin/paclitaxel, one because of advanced 
age, one because of cardiac diastolic dysfunction and 
one because of pre-existing tinnitus. Two patients re-
ceived carboplatin/gemcitabine because of preexisting 
neuropathy and one received carboplatin/vinorelbine 
because of prior toxicity to cisplatin during previous 
treatment for lymphoma. The median duration from 
surgery to chemotherapy was 10 weeks (range 6-24 
weeks). Only two patients (4%) had received adjuvant 
radiation because of microscopic involvement of the 
margins before starting chemotherapy. 
Treatment delivery 
Three patients started chemotherapy at a reduced dose 
Table 3. Compliance with treatment. 
Modification of treatment Number (%) (n=50) 
Dose reduction 
   Yes 20 (40) 
   No 30 (60) 
Delay of chemotherapy 
   Yes 29 (58) 
   No 21 (42) 
Total number of cycles 
   4 cycles 40 (80) 
   3 cycles 6 (12) 
   1½ cycle 2 (4) 
   1 cycle 1 (2) 
   <1 cycle 1 (2) 
Cisplatin received* 
   median dose 276.9 mg/m
2 (92.5% of the 
full dose) 
   mean dose 240.1 mg/m2 
Vinorelbin received** 
   median dose 191.1 mg/m
2 (95.5% of the 
total dose) 
   mean dose 165.3 mg/m2 
*For 44 patients (88%).  **For 42 patients (84%).
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because of advanced age, sensory neuropathy, ototox-
icity and renal impairment. Seventeen patients (34%) 
required a dose reduction during therapy (5 for neutro-
penia, 5 for infections, 4 for fatigue, nausea and vom-
iting, 2 for neurotoxicity and 1 for renal impairment). 
A total of 29 patients (58%) had a delay in treatment, 
16 because of prolonged neutropenia, 2 because of con-
current infection, 2 because of Christmas holidays, 2 
because of fatigue and vomiting, while 2 patients were 
scheduled for every 4-week chemotherapy because of 
advanced age; one patient requested a delay and 4 were 
delayed for unknown reasons (Table 3). 
Forty patients (80%) completed all planned treat-
ment cycles (Table 3). Six (12%) received 3 cycles, 2 
(4%) had one and half cycles, one completed one cycle 
and one received only day 1 of the cycle. The reasons for 
discontinuation of treatment included fatigue, nausea 
and vomiting in 5 patients, myocardial infarction, pul-
monary embolism, febrile neutropenia and prolonged 
neutropenia in one patient each. Only one patient dis-
continued treatment in the absence of objective toxicity. 
For the 44 patients (88%) who received cisplatin-based 
therapy, the median cisplatin dose delivered was 276.9 
mg/m2 (92.5% of the full dose) with a mean dose of 
240.1 mg/m2. On the other hand, and of the 42 patients 
(84%) who received vinorelbine, the median dose deliv-
ered was 191.1 mg/m2 (95.5% of the full dose) with a 
mean dose of 165.3 mg/m2.
Toxicity 
Grade 3-4 toxicities are shown in Table 4. There were 
6 episodes of febrile neutropenia in 5 patients (10%), 
and 5 patients (10%) were admitted to hospital for 
treatment-related toxicity (4 patients with febrile neu-
tropenia and one with esophageal candidiasis). Another 
2 (4%) required hospitalization for reasons unrelated to 
treatment (one myocardial infarction and one pulmo-
nary embolism). 
Association with clinical factors 
Age at diagnosis, gender, extent of surgery (pneumectomy 
versus lesser resection) and ECOG performance status 
(0-1 versus 2) were all tested for their association with 
the rate of compliance and severity of toxicity. Table 5 
summarizes the analysis for the 44 patients who received 
cisplatin-based chemotherapy. None of these factors was 
associated with either compliance or toxicity.
DISCUSSION 
After the unequivocal demonstration of significant sur-
vival benefits in the recent randomized trials that used 
“third-generation” platinum-based chemotherapy regi-
mens, adjuvant chemotherapy for resected, early stage 
NSCLC has become the standard of care in North 
America and Europe.3-7 Interestingly, these significant 
results were obtained despite very poor compliance 
with chemotherapy in all of the trials that used cispla-
tin-containing regimens.10 The NCIC CTG JBR.10 
trial that used cisplatin/vinorelbine, showed a survival 
advantage of 15% at 5 years even though only 48% of 
patients completed all four planned cycles of treat-
ment.4 With the exception of the CALGB 9633 trial 
that employed a carboplatin-based regimen, and actual-
ly showed no significant advantage in overall survival in 
the latest update,6 all other randomized trials reported 
similar compliance rates. Inadequate dose delivery has 
been postulated to be one of the most important factors 
responsible for the poor results achieved in the early tri-
als of the 1970s and 1980s.11 
We questioned whether the lack of compliance 
may have been due, in part, to a perceived notion on 
the part of both physicians and patients that adjuvant 
chemotherapy was unlikely to result in any significant 
long-term benefit.13 Certainly, this belief would be un-
derstandable given the negative results of many ran-
domized trials.14-16 If patients and physicians felt that 
Table 4. Toxicity. 
Toxicity Number (%) (n=50) 
Grade 3-4 non-hematologic toxicity 
   Fatigue 5 (10) 
   Anorexia 2 (4) 
   Nausea 2 (4) 
   Vomiting 1 (2) 
   Diarrhea 1(2) 
   Constipation 1 (2) 
   Hearing loss 0 
   Sensory or motor neuropathy 0 
Grade 3-4 hematologic toxicity 
   Anemia 2 (4) 
   Neutropenia 14 (28) 
   Thrombocytopenia 1 (2) 
   Febrile neutropenia 5 (10) 
   Toxicity related admission 5 (10) 
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benefit was unlikely, they might be unwilling to accept 
even modest degrees of toxicity, and would discontinue 
treatment even if those toxicities were rapidly revers-
ible and not associated with long-term sequelae. We 
postulated that if patients could be convinced that 
adjuvant chemotherapy offered a significant chance of 
prolonged survival and perhaps the possibility of an 
increased cure rate, they would be more willing to ac-
cept short-term toxicity, and “soldier through” to the 
end of treatment. Our review of patients treated at our 
institution in the two years after the publication of the 
positive trials, supports this viewpoint. Eighty percent 
of patients completed all four cycles of planned chemo-
therapy. Moreover, for the patients who received cis-
platin-based or vinorelbine-based therapy, the median 
doses of both cisplatin and vinorelbine delivered were 
greater than 90% of the planned dose. This is similar to 
the 85% compliance rate reported in the CALGB trial 
that used paclitaxel/carboplatin, a slightly less emeto-
genic regimen.5 Better compliance with paclitaxel/car-
boplatin over cisplatin/vinorelbine was found also in a 
randomized trial in advanced NSCLC17 in which 27% 
of patients on the paclitaxel/carboplatin arm completed 
therapy as planned versus 15% of patients on the cispla-
tin/vinorelbine arm (P=.008). However, the main rea-
son to stop treatment in both arms was disease progres-
sion rather than toxicity. In this study, 40% of patients 
required at least one dose reduction compared to 77% 
in the JBR.10 trial that used the same chemotherapy 
drugs. This difference may have been due to the modi-
fied schedule of cisplatin/vinorelbine that is now used 
at our institutions. 
Cisplatin 75 mg/m2 is given with vinorelbine 25 
mg/m2 on day 1 and 8 in a 3-week cycle rather than 
cisplatin 50 mg/m2 on day 1 and 8 with the weekly 
vinorelbine given in the JBR.10 trial. Recently, Gebbia18 
compared the SWOG regimen with weekly vinorelbine 
and cisplatin to vinorelbine only on day 1 and 8 and 
cisplatin in a randomized phase 3 trial and found that 
both arms had the same response rate, progression-free 
survival and overall survival. The day 1+8 vinorelbine 
regimen was better tolerated with a lower rate of grade 
4 hematological toxicity, treatment omissions, and ther-
apy discontinuations. 
It has been postulated that the administration of 
chemotherapy to lung cancer patients in the postopera-
tive period remains a challenge because of the debiliting 
effects of major thoracic surgery.19 Alam reported that 
compliance in JBR.10 was lower for patients who had 
undergone complete pneumonectomy.11 In our study, 
Table 6. Compliance and toxicity in JBr. 10 trial4 and current 
study.
JBR-10 trial Current study 
Completion of treatment 48% 80% 
Grade 3-4 toxicity 
   Neutropenia 73% 28% 
   Fatigue 15% 10% 
   Nausea / vomiting 10%/17% 4%/2% 
   Febrile neutropenia 7% 10% 
   Toxicity-related       
   admission 19% 10% 
   Toxic death 0.8% 0 
Table 5. multivariate analysis for 44 patients treated with cisplatin-based regimens..
Age Gender Type of surgery Performance status
≤64 ≥65 male Female Pneumo-nectomy
Lesser 
resection 0-1 2
All patients
(n=44) 23 21 21 23 6 38 36 8
Completion of 
treatment cycles
(n=40)
22 (96%) 18 (86%) 18 (86%) 22 (96%) 5 (83%) 35 (92%) 33 (92%) 7 (88%)
P=.33 P=.33 P=.46 P=.57
Grade 3-4 neutropenia
(n=13)
6 (26%) 7 (33%) 6 (29%) 7 (30%) 3 (50%) 10 (26%) 10 (28%) 3 (38%)
P=.74 P>.99 P=.34 P=.68
Febrile neutropenia 
(n=4)
2 (9%) 2 (10%) 1 (5%)  3 (13%) 1 (17%) 3 (8%) 3 (8%) 1 (13%)
P>.99 P=.61 P=.46 P=.57
Total admissions*
(n=6)
2 (9%) 4 (19%) 1 (5%) 5 (22%) 1 (17%) 5 (13%) 5 (14%) 1 (13%)
P=.40 P=.19 P>.99 P>.99
*Includes toxicity related and unrelated admissions
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compliance was excellent even for pneumonectomy pa-
tients, with more than 80% completing all four cycles 
of therapy. 
Some investigators have suggested that induction 
chemotherapy prior to surgery might be superior to 
post-operative adjuvant chemotherapy since compli-
ance in most neoadjuvant trials has been in the 80% 
range.20-23 However, most induction protocols have 
called for only two or three courses of pre-operative 
chemotherapy, and so it appears that the total doses and 
number of cycles of chemotherapy that can be delivered 
pre-operatively and post-operatively are now similar. 
Induction versus adjuvant chemotherapy was evaluated 
in a European trial and the mature survival results are 
expected in 2009.24
The patient’s role in stopping treatment was signifi-
cant in the JBR.10 trial with patient refusal the reason 
for discontinuing treatment in 29% of patients, in com-
parison to toxicity in only 13%. In this study, patient 
refusal and toxicity were reasons for treatment discon-
tinuation in only 2% and 10% of patients, respectively. 
This clearly suggests that adjuvant cisplatin-based che-
motherapy is becoming accepted by both physicians 
and patients with a high degree of compliance in daily 
clinical practice.
The results of the recent large randomized trials of 
adjuvant chemotherapy have led to a paradigm shift in 
the management of completely resected NSCLC. The 
potential for improved survival undoubtedly will lead 
to greater motivation on the part of both physicians 
and patients to complete the treatment, and it is likely 
that adjuvant chemotherapy trials of the future will be 
associated with higher compliance rates. Improvement 
of compliance in this relatively small retrospective study 
may also have been due to the modified schedule of cis-
platin/vinorelbine that is now used at our institutions. 
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